

K023375

Page 1 of 2

510 (K) SUMMARY – ESOP® Co-Cr Femoral Head

OCT 25 2002

Submitter name: Fournitures Hospitalières Industrie

Submitter address: 6 Rue Nobel, Z.I. de Kernevez
QUIMPER, France 29000

Contact person: Mrs Christine QUENDEZ

Phone Number: +33.2.98.55.68.95
Fax Number: +33.2.98.53.42.13

Date prepared: October 4, 2002

Device Trade Name: ESOP® Co-Cr Femoral Head

Device common name: Femoral head

Classification name: Hip joint metal/polymer/metal semi-constrained porous-coated uncemented prosthesis

Predicate Device: ESOP® Co-Cr Femoral Heads (K021109), Fournitures Hospitalières Industrie

Total Hip Femoral Head – 12/14 Taper (K021673), Smith & Nephew, Inc.

Device description: The Metallic Femoral Heads are intended to be adapted to special cones machined for this purpose. Femoral head are available in several diameters for use in full hip or intermediary replacement. The length of the neck on the femoral stem can be adjusted by using the heads available in different insertion depths (short, medium, long and extra-long collars), and of different diameters.

Intended use: Prosthetic replacement of the femoral head associated with hip prosthesis, which cone is compatible with the head's cone and with a prosthetic acetabular cup, whose diameter is compatible with the head.

K023375

Page 2 of 2

**Device Technological
Characteristics and
Comparison to Predicate
Devices:**

Femoral heads made of chrome cobalt (Ø 22, 28 & 32 mm), short collar, medium collar, long collar & extra-long collar with cone dimensions 12/14, 5°43' & 10/12, 6°. The identified predicate devices have the same intended use, are made of the same material, have the same size, and collar + cone dimensions are of the same order of magnitude.

Performance Data:

Verification/validation and design control activities demonstrate the safety and effectiveness of the ESOP® Co-Cr Femoral Heads.

Conclusion:

The ESOP® Co-Cr Femoral Heads are substantially equivalent to predicate devices in terms of intended use, safety, and effectiveness.



Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

OCT 25 2002

Dr. Andre Weith
Director, Pro-Active Healthcare
c/o Pharmanet, Inc.
815 Connecticut Ave., NW
Suite 800
Washington, DC 20006

Re: K023375

Trade/Device Name: ESOP® Co-Cr Femoral Heads

Regulation Number: 21 CFR 888.3358

Regulation Name: Hip joint metal/polymer/metal semi-constrained porous-coated
uncemented prosthesis

Regulatory Class: Class II

Product Code: LPH

Dated: October 4, 2002

Received: October 8, 2002

Dear Dr. Weith:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set


Page 2 – Dr. Andre Weith

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>

Sincerely yours,

A handwritten signature in black ink, appearing to read "Celia M. Witten", is written over a horizontal line.

Celia M. Witten, Ph.D., M.D.

Director

Division of General, Restorative
and Neurological Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

Applicant:
Pro-Active

ESOP® Co-Cr Femoral Heads
Special 510(k) Premarket Notification

510(k) Number (if known):

K023375

Device Name:

ESOP® Co-Cr Femoral Heads

Indications for Use:

The ESOP® Co-Cr Femoral Heads are intended for use in degenerative and inflammatory arthritis of the hip joint, trauma, non-acute femoral neck fracture, revision of previously failed hip arthroplasties, and idiopathic avascular (osteo) necrosis where radiographic evidence shows there is sufficient sound bone to seat the prosthesis. This device is intended for cementless application.


(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF
NEEDED)

Concurrence of CDRH; Office of Device Evaluation (ODE)

Prescription
Use
(Per 21 CFR 801.109)

OR

Over-The-Counter
Use

 (Optional Format 1-2-96)
(Division Sign-Off)
Division of General, Restorative
and Neurological Devices

510(k) Number

K023375